Expression of dog microdystrophin in mouse and dog muscles by gene therapy

Molecular Therapy

Volumn 18, Issue 5, 2010, Pages 1002-1009

  Pichavant, Christophe ^a   Chapdelaine, Pierre ^a   Cerri, Daniel G ^a   Dominique, Jean Christophe ^a   Quenneville, Simon P ^a   Skuk, Daniel ^a   Kornegay, Joe N ^b   Bizario, Joo Cs ^c   Xiao, Xiao ^b   Tremblay, Jacques P ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DYSTROPHIN; LENTIVIRUS VECTOR; MICRODYSTROPHIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DUCHENNE MUSCULAR DYSTROPHY; ELECTROPORATION; EX VIVO GENE TRANSFER; EXPERIMENTAL ANIMAL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; MUSCLE CELL; NONHUMAN; PLASMID; STEM CELL TRANSPLANTATION; TRANSGENE;

ANIMALS; BLOTTING, WESTERN; CELL LINE; DOGS; DYSTROPHIN; GENE THERAPY; HUMANS; LENTIVIRUS; MICE; MICE, MUTANT STRAINS; MUSCLES; MUSCULAR DYSTROPHY, DUCHENNE; PLASMIDS; STEM CELLS;

ANIMALIA; CANIS FAMILIARIS; LENTIVIRUS; PRIMATES;

EID: 77952012209     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.23     Document Type: Article

References (43)

1. Hoffman, EP, Brown, RH Jr and Kunkel, LM (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919-928.
2. Campbell, KP and Kahl, SD (1989). Association of dystrophin and an integral membrane glycoprotein. Nature 338:259-262.
3. Ervasti, JM and Campbell, KP (1991). Membrane organization of the dystrophinglycoprotein complex. Cell 66:1121-1131.
4. Aartsma-Rus, A and van Ommen, GJ (2010). Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet 18:146-153.
5. Péault, B, Rudnicki, M, Torrente, Y, Cossu, G, Tremblay, JP, Partridge, T et al. (2007). Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 15:867-877. (Pubitemid 46621645)
6. Skuk, D, Roy, B, Goulet, M, Chapdelaine, P, Bouchard, JP, Roy, R et al. (2004). Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells. Mol Ther 9:475-482.
7. Skuk, D, Goulet, M, Roy, B, Piette, V, Côté, CH, Chapdelaine, P et al. (2007). First test of a 'high-density injection' protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord 17:38-46.
8. Sampaolesi, M, Blot, S, D'Antona, G, Granger, N, Tonlorenzi, R, Innocenzi, A et al. (2006). Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 444:574-579.
9. Wang, Z, Kuhr, CS, Allen, JM, Blankinship, M, Gregorevic, P, Chamberlain, JS et al. (2007). Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15:1160-1166.
10. Ohshima, S, Shin, JH, Yuasa, K, Nishiyama, A, Kira, J, Okada, T et al. (2009). Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 17:73-80.
11. Moisset, PA, Skuk, D, Asselin, I, Goulet, M, Roy, B, Karpati, G et al. (1998). Successful transplantation of genetically corrected DMD myoblasts following ex vivo transduction with the dystrophin minigene. Biochem Biophys Res Commun 247:94-99.
12. Quenneville, SP, Chapdelaine, P, Skuk, D, Paradis, M, Goulet, M, Rousseau, J et al. (2007). Autologous transplantation of muscle precursor cells modified with a lentivirus for muscular dystrophy: human cells and primate models. Mol Ther 15:431-438.
13. Zaiss, AK and Muruve, DA (2008). Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 15:808-816.
14. Romero, NB, Braun, S, Benveniste, O, Leturcq, F, Hogrel, JY, Morris, GE et al. (2004). Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther 15:1065-1076.
15. Mir, LM, Bureau, MF, Gehl, J, Rangara, R, Rouy, D, Caillaud, JM et al. (1999). High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 96:4262-4267.
16. Bodles-Brakhop, AM, Heller, R and Draghia-Akli, R (2009). Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 17:585-592.
17. Kinoshita, I, Vilquin, JT, Guérette, B, Asselin, I, Roy, R and Tremblay, JP (1994). Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 17:1407-1415.
18. Harris, JB and Johnson, MA (1978). Further observations on the pathological responses of rat skeletal muscle to toxins isolated from the venom of the Australian tiger snake, Notechis scutatus scutatus. Clin Exp Pharmacol Physiol 5:587-600.
19. Floyd, SS Jr, Clemens, PR, Ontell, MR, Kochanek, S, Day, CS, Yang, J et al. (1998). Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther 5:19-30.
20. Miranda, AF, Bonilla, E, Martucci, G, Moraes, CT, Hays, AP and Dimauro, S (1988). Immunocytochemical study of dystrophin in muscle cultures from patients with Duchenne muscular dystrophy and unaffected control patients. Am J Pathol 132:410-416.
21. Jaynes, JB, Johnson, JE, Buskin, JN, Gartside, CL and Hauschka, SD (1988). The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer. Mol Cell Biol 8:62-70.
22. Zhu, CH, Mouly, V, Cooper, RN, Mamchaoui, K, Bigot, A, Shay, JW et al. (2007). Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell 6:515-523.
23. Mir, LM (2009). Nucleic acids electrotransfer-based gene therapy (electrogenetherapy): past, current, and future. Mol Biotechnol 43:167-176.
24. Trollet, C, Scherman, D and Bigey, P (2008). Delivery of DNA into muscle for treating systemic diseases: advantages and challenges. Methods Mol Biol 423:199-214.
25. Vilquin, JT, Wagner, E, Kinoshita, I, Roy, R and Tremblay, JP (1995). Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin. J Cell Biol 131:975-988.
26. Ohtsuka, Y, Udaka, K, Yamashiro, Y, Yagita, H and Okumura, K (1998). Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: implication for gene therapy. J Immunol 160:4635-4640.
27. Roy, R, Tremblay, JP, Huard, J, Richards, C, Malouin, F and Bouchard, JP (1993). Antibody formation after myoblast transplantation in Duchenne-dystrophic patients, donor HLA compatible. Transplant Proc 25 (1 Pt 2):995-997.
28. Wang, B, Li, J, Qiao, C, Chen, C, Hu, P, Zhu, X et al. (2008). A canine minidystrophin is functional and therapeutic in mdx mice. Gene Ther 15:1099-1106.
29. Kornegay, JN, Li, J, Bogan, JR, Bogan, DJ, Chen, C, Qiao, C, et al. (2009). Widespread muscle expression of an AAV-9 human mini-dystrophin construct after systemic intravenous injection in golden retriever muscular dystrophy (GRMD) neonatal dogs. Mol Ther 17 (suppl 1): S152-S153.
30. Li, J, Bogan, J, Chen, C, Bogan, D, Wang, B, Yuan, Z, et al. (2009). Hydrodynamic limb vein injection of AAV9 results in regional and systemic long-term expression of minidystrophin in young adult GRMD dogs. Mol Ther 17 (supp 1): S278.
31. Yue, Y, Ghosh, A, Long, C, Bostick, B, Smith, BF, Kornegay, JN et al. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 16:1944-1952.
32. Stone, D, Liu, Y, Li, ZY, Strauss, R, Finn, EE, Allen, JM et al. (2008). Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery. J Virol 82:7711-7715.
33. Douglas, JT (2007). Adenoviral vectors for gene therapy. Mol Biotechnol 36:71-80.
34. Stolberg, SG (1999). F. D. A. Officials Fault Penn Team in Gene Therapy Death. New York Times (Print): p. A22.
35. Porteus, MH, Connelly, JP and Pruett, SM (2006). A look to future directions in gene therapy research for monogenic diseases. PLoS Genet 2: e133.
36. Skuk, D, Goulet, M, Roy, B, Chapdelaine, P, Bouchard, JP, Roy, R et al. (2006). Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol 65:371-386.
37. Bartlett, RJ, Winand, NJ, Secore, SL, Singer, JT, Fletcher, S, Wilton, S et al. (1996). Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs. Am J Vet Res 57:650-654.
38. Wang, B, Li, J and Xiao, X (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 97:13714-13719.
39. Chapdelaine, P, Moisset, PA, Campeau, P, Asselin, I, Vilquin, JT and Tremblay, JP (2000). Functional EGFP-dystrophin fusion proteins for gene therapy vector development. Protein Eng 13:611-615.
40. Dull, T, Zufferey, R, Kelly, M, Mandel, RJ, Nguyen, M, Trono, D et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463-8471.
41. Salmon, P and Trono, D (2006). Production and titration of lentiviral vectors. Curr Protoc Neurosci Chapter 4: Unit 4.21.
42. Morgan, JE, Hoffman, EP and Partridge, TA (1990). Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J Cell Biol 111 (6 Pt 1):2437-2449.
43. Wakeford, S, Watt, DJ and Partridge, TA (1991). X-irradiation improves mdx mouse muscle as a model of myofiber loss in DMD. Muscle Nerve 14:42-50.